PY: Resources, Formal Analysis, Writingoriginal draft, Writingreview and editing
Stiede, K
Disclosures: Meng Huang: Enanta Pharmaceuticals: Employee, Khanh Hoang: Nothing to Disclose, Jonathan Kibel: Nothing to Disclose, Shucha Zhang: Nothing to Disclose, Lisha Xu: Nothing to Disclose, Yang Li: Nothing to Disclose, Indy Zang: Nothing to Disclose, Daniel Leonard: Nothing to Disclose, Siu-Lung Chan: Nothing to Disclose, Joshua Klaene: Nothing to Disclose, Yat Sun Or: Nothing to Disclose, Li-Juan Jiang: Nothing to Disclose 453 INCREASING RISK OF METABOLIC COMORBIDITIES IN PATIENTS WITH HBV MONOINFECTION, HBV/HCV COINFECTION, AND HBV/HIV COINFECTION: A NATIONWIDE POPULATION-BASED STUDY Jae Yoon Jeong 1 Won Sohn 2 Hyun Woo Oh 2 Hyo Young Lee 3 Na Ryung Choi 1 Yeonjae Kim 4 Jung Hee Kim 5 , 1 Ewha Womans University Mokdong Hospital, College of Medicine, Ewha Womans University, 2 Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, 3 Inje University Sanggye Paik Hospital, 4 National Medical Center, 5 Dongtan Sacred Heart Hospital of Hallym University Medical Center Background: The use of antiviral therapy in patients with chronic hepatitis B (CHB) has consistently improved survival rates and a positive impact on metabolic comorbidities
However, subgroup analyses by putative influencing factors found considerable variance across subgroups
Sufficient clinical evidence is available to recommend the use of NAC or carbocisteine as an addition to current therapies in certain patients with COPD, at least in the hope of reducing the number of respiratory exacerbations and possibly improving the health-related quality of life
